Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Published: Jul, 2016 | Pages: 85 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B)  - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B)  targeted pipeline therapeutics. 

The report provides comprehensive information on the Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B)  targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) 
- The report reviews Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B)  targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B)  targeted therapeutics and enlists all their major and minor projects 
- The report assesses Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B)  targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B)  targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B)  development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Overview 8
Therapeutics Development 9
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Stage of Development 9
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Therapy Area 10
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Indication 11
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Companies 15
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Universities/Institutes 18
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Therapeutics Assessment 20
Assessment by Monotherapy/Combination Products 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Companies Involved in Therapeutics Development 26
AbbVie Inc 26
Affibody AB 27
Anacor Pharmaceuticals, Inc. 28
Apexigen, Inc. 29
Cell Medica Limited 30
Handok Inc. 31
Immune Response BioPharma, Inc. 32
Novartis AG 33
Omnitura Therapeutics Inc. 34
Opsona Therapeutics Limited 35
Peptinov SAS 36
R-Pharm 37
Regeneron Pharmaceuticals Inc 38
TWi Pharmaceuticals, Inc. 39
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Drug Profiles 40
ABT-981 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
AN-4161 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
APX-002 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
canakinumab - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
diacerein - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
DLX-2323 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
DLX-2681 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
HL-2351 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
IR-1000 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
IR-1002 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
IR-888 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
melittin - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
OMN-54 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
PPV-01 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Recombinant Protein to Inhibit IL-1 Beta for Autoimmune Disorder and Inflammation - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
rilonacept - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
RPH-104 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Small Molecule Inflammasome Modulator Programme - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Dormant Projects 67
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Discontinued Products 72
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Featured News & Press Releases 75
Jun 27, 2016: TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment 75
Jun 23, 2016: CHMP adopts extension to existing therapeutic indication for Canakinumab 75
Apr 27, 2016: Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes 76
Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir 76
Mar 23, 2016: Turkish signature on the biomolecules study - Hurriyet 77
Dec 24, 2015: TWi Biotechnology Reports Positive Interim Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients 78
Nov 03, 2015: AbbVie to present abstract on ABT-981 at the American College of Rheumatology Annual Meeting 79
Oct 27, 2015: TWi Biotechnology Receives Notice of Patent Allowance in Korea for its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes 79
Aug 03, 2015: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in Europe and Russia 80
Mar 10, 2015: TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan 80
Dec 22, 2014: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 81
Dec 12, 2014: TWi Biotechnology Receives Approval of Protocol for Its Drug AC-201 Controlled-Release Tablet, Phase II Clinical Trial in Both the United States and Taiwan 81
Oct 21, 2014: TWi Biotechnology Receives Orphan Drug Designation for its Lead Drug Candidate AC-201 In United States 81
Jun 26, 2014: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 in United States 82
Sep 10, 2013: TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in the United States 82
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 84
Disclaimer 85

List of Tables

Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Assessment by Monotherapy/Combination Products, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Pipeline by AbbVie Inc, H2 2016 26
Pipeline by Affibody AB, H2 2016 27
Pipeline by Anacor Pharmaceuticals, Inc., H2 2016 28
Pipeline by Apexigen, Inc., H2 2016 29
Pipeline by Cell Medica Limited, H2 2016 30
Pipeline by Handok Inc., H2 2016 31
Pipeline by Immune Response BioPharma, Inc., H2 2016 32
Pipeline by Novartis AG, H2 2016 33
Pipeline by Omnitura Therapeutics Inc., H2 2016 34
Pipeline by Opsona Therapeutics Limited, H2 2016 35
Pipeline by Peptinov SAS, H2 2016 36
Pipeline by R-Pharm, H2 2016 37
Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 38
Pipeline by TWi Pharmaceuticals, Inc., H2 2016 39
Dormant Projects, H2 2016 67
Dormant Projects (Contd..1), H2 2016 68
Dormant Projects (Contd..2), H2 2016 69
Dormant Projects (Contd..3), H2 2016 70
Dormant Projects (Contd..4), H2 2016 71
Discontinued Products, H2 2016 72
Discontinued Products (Contd..1), H2 2016 73
Discontinued Products (Contd..2), H2 2016 74